Taurolidine treatment for myc-expressing tumors in mammalian bodies

Abstract

A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising: administering a composition to the mammalian body, wherein the composition comprises at least one from the group consisting of taurolidine; taurultam; taurinamide; methylene glycol; taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide; and taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol.

What is claimed is: 
     
         1 . A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising:
 administering a composition to the mammalian body, wherein the composition comprises at least one from the group consisting of:   taurolidine;   taurultam;   taurinamide;   methylene glycol;   taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide; and   taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol.   
     
     
         2 . A method according to  claim 1  wherein the composition comprises taurolidine. 
     
     
         3 . A method according to  claim 2  wherein the dosage range is from 5 mg/kg to 280 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         4 . A method according to  claim 3  wherein the dosage range is from between 5 mg/kg and 60 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         5 . A method according to  claim 2  wherein the composition is administered in conjunction with an oncolytic agent and/or radiotherapy. 
     
     
         6 . A method according to  claim 1  wherein the composition comprises taurultam. 
     
     
         7 . A method according to  claim 6  wherein the dosage range is from 5 mg/kg to 280 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         8 . A method according to  claim 7  wherein the dosage range is from between 5 mg/kg and 60 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         9 . A method according to  claim 6  wherein the composition is administered in conjunction with an oncolytic agent and/or radiotherapy. 
     
     
         10 . A method according to  claim 1  wherein the composition comprises taurinamide. 
     
     
         11 . A method according to  claim 10  wherein the dosage range is from 5 mg/kg to 280 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         12 . A method according to  claim 11  wherein the dosage range is from between 5 mg/kg and 60 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         13 . A method according to  claim 10  wherein the composition is administered in conjunction with an oncolytic agent and/or radiotherapy. 
     
     
         14 . A method according to  claim 1  wherein the composition consists of methylene glycol. 
     
     
         15 . A method according to  claim 14  wherein the dosage range is from 2.5 mg/kg to 160 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         16 . A method according to  claim 15  wherein the dosage range is from between 2.5 mg/kg and 30 mg/kg from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         17 . A method according to  claim 14  wherein the composition is administered in conjunction with an oncolytic agent and/or radiotherapy. 
     
     
         18 . A method according to  claim 1  wherein the composition consists of taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide. 
     
     
         19 . A method according to  claim 18  wherein the dosage range for taurultam is from 5 mg/kg to 280 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         20 . A method according to  claim 19  wherein the dosage range for taurultam is from 5 mg/kg to 40 mg/kg, combined with taurinamide with a dosage range of from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         21 . A method according to  claim 18  wherein the composition is administered in conjunction with an oncolytic agent. 
     
     
         22 . A method according to  claim 1  wherein the composition consists of taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol. 
     
     
         23 . A method according to  claim 22  wherein the dosage range for taurultam is from 5 mg/kg to 280 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         24 . A method according to  claim 23  wherein the dosage range for taurultam is optimally from 5 mg/kg to 40 mg/kg, combined with taurinamide with a dosage range of from 35 mg/kg to 40 mg/kg, combined with methylene glycol with a dosage range of from 5 mg/kg to 40, from once daily through weekly, for an effective period of time based on individual patient response. 
     
     
         25 . A method according to  claim 22  wherein the composition is administered in conjunction with an oncolytic agent and/or radiotherapy. 
     
     
         26 . A method according to  claim 1  wherein the composition is delivered to the patient using one from the group consisting of parenteral delivery, intramuscular delivery and intravenous delivery. 
     
     
         27 . A method according to  claim 1  wherein the composition is included in a nanoparticle, and further wherein the nanoparticle is configured to delay exposure of the composition until the nanoparticle reaches the site of a tumor. 
     
     
         28 . A method according to  claim 27  wherein the nanoparticle comprises a core of the composition and an exterior coating, wherein the exterior coating is configured to prevent exposure of the composition prior to arrival of the nanoparticle at the site of the tumor. 
     
     
         29 . A method according to  claim 28  wherein the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor. 
     
     
         30 . A method according to  claim 1  wherein the composition is delivered using a polymer system which is configured to delay premature degradation of the composition. 
     
     
         31 . A method according to  claim 30  wherein the composition is “pegylated” using polyethylene glycols (PEGs) to delay premature degradation of the composition.